VivoSeq
Infectious Disease

SARS-Cov-2

0

Pipeline Programs↗

3

Active Trials↗

6

Companies Involved↗

SARS-CoV-2 is an early-stage landscape with 0 programs across 6 companies. The most active players are Livzon Pharmaceutical Group Inc., GSK, Ridgeback Biotherapeutics, LP.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

L

Livzon Pharmaceutical Group Inc.

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalR

Ridgeback Biotherapeutics, LP

0 programs

PreclinicalY

Yisheng Biopharma (Singapore) Pte. Ltd.

0 programs

PreclinicalY

Yantai Patronus Biotech Co., Ltd.

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

37

clinical trials

Completed25 · 68%
Unknown status5 · 14%
Withdrawn3 · 8%
Active, not recruiting1 · 3%
Not yet recruiting1 · 3%
Recruiting1 · 3%
Other1 · 3%

Clinical Trials

Trial Activity

37 trials

Understanding the Determinants of Mucosal Immunity and Optimizing the Diagnosis of Infection With SARS-CoV-2 Variants
Recruiting·IInstitut Pasteur·N/A·NCT05858502·90 enrolled
Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI
Active, not recruiting·NNYU Langone Health·N/A·NCT05615415·30 enrolled
Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants
Not yet recruiting·IImperial College London·Phase 1·NCT07397455·38 enrolled
A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults
Completed·GSK logoGSK·Phase 1·NCT06680375·106 enrolled
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study
Completed·LLivzon Pharmaceutical Group Inc.·Phase 3·NCT05096832·10,381 enrolled
Study of the Specific Seroprevalence of SARS-CoV-2 in a Sample of Patients and Salaried Staff From a French Anti-cancer Center at the End of the Containment Period of the SARS-CoV-2 Pandemic
Completed·CCentre Georges Francois Leclerc·N/A·NCT04517097·1,680 enrolled
The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)
Completed·RRidgeback Biotherapeutics, LP·Phase 2·NCT04405739·71 enrolled
A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.
Completed·YYisheng Biopharma (Singapore) Pte. Ltd.·Phase 2/3·NCT05463419·5,860 enrolled
Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects
Completed·SSinocelltech Ltd.·Phase 1·NCT04483375·33 enrolled
Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines
Completed·NNovavax·Phase 3·NCT05372588·1,340 enrolled
Humoral and Cellular Immunity Against SARS-COV-2 Vaccine in HIV-infected Patients Immunosuppressed
Completed·HHospitales Universitarios Virgen del Rocío·N/A·NCT05633927·48 enrolled
A Strain Change Study for SARS-CoV-2 rS Vaccines
Completed·NNovavax·Phase 3·NCT06409663·60 enrolled
SARS-CoV-2 Human Challenge Characterisation Study
Completed·IImperial College London·N/A·NCT04865237·36 enrolled
Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence
Completed·LLaboratorio Avi-Mex, S.A. de C.V.·Phase 2·NCT05205746·158 enrolled
Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms
Completed·IInvestigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.·Phase 2·NCT04407507·66 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)